Login to Your Account

In enzyme-target bid, $30M series A cash fuels Disarm

By Randy Osborne
Staff Writer

Tuesday, September 19, 2017

For scientists aiming to combat the long-known problem of axonal degeneration, "the issue was that there wasn't a lever to pull, there wasn't a drug target," Disarm Therapeutics Inc.'s acting CEO, Jason Rhodes, told BioWorld.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription